PHILADELPHIA (Legal Newsline) – A $7.3 million settlement has been reached with drugmaker Astellas Pharma US Inc. over claims that it violated the False Claims Act by illegally marketing the antifungal drug Mycamine to children.
The settlement was announced Wednesday by a team of whistleblower lawyers from Philadelphia-based Sheller P.C.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.